Dare Bioscience (NASDAQ:DARE) Stock Crosses Below 200-Day Moving Average – Time to Sell?

by · The Markets Daily

Shares of Dare Bioscience, Inc. (NASDAQ:DARE – Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.79 and traded as low as $0.74. Dare Bioscience shares last traded at $0.74, with a volume of 246,949 shares.

Analysts Set New Price Targets

A number of analysts have commented on DARE shares. HC Wainwright reiterated a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. Weiss Ratings upgraded Dare Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Wall Street Zen upgraded Dare Bioscience to a “hold” rating in a research note on Saturday, May 23rd. Finally, Benchmark reaffirmed a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $12.00.

Read Our Latest Report on Dare Bioscience

Dare Bioscience Price Performance

The firm has a market cap of $14.36 million, a P/E ratio of -1.04 and a beta of 1.01. The stock’s 50 day moving average is $1.39 and its two-hundred day moving average is $1.78.

Dare Bioscience (NASDAQ:DARE – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, research analysts forecast that Dare Bioscience, Inc. will post -0.69 EPS for the current fiscal year.

Institutional Trading of Dare Bioscience

Several institutional investors have recently bought and sold shares of DARE. LPL Financial LLC bought a new stake in Dare Bioscience in the fourth quarter valued at $28,000. Raymond James Financial Inc. boosted its stake in shares of Dare Bioscience by 810.6% in the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Dare Bioscience in the 3rd quarter valued at $37,000. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Dare Bioscience

(Get Free Report)

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.

Recommended Stories